Vaccination against hepatitis a in patients with chronic liver disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hepatitis A virus (HAV) superinfection is associated with a high risk of liver failure and death in patients with underlying chronic liver disease. HAV vaccination is effective and safe, although the vaccine is less immunogenic in patients with advanced liver disease. Despite recommendations to immunize patients with chronic liver disease, rates of HAV vaccination remain low, thus highlighting the need for public health programs to increase awareness about HAV vaccination.
- Centers for Disease Control and Prevention: Disease burden from hepatitis A, B, and C in the United States. http://www.cdc.gov/ncidod/diseases/hepatitis/resource/ dz_burden02.htm. Accessed December 13, 2005.
- Berge JJ, Drennan DP, Jacobs RJ, et al.: The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000, 31:469–473. CrossRef
- Centers for Disease Control and Prevention: Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996, 45:1–30. [Published erratum appears in MMWR Morb Mortal Wkly Rep 1997, 46:588.]
- National Institutes of Health: National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 2002, 36(5 Suppl 1):S3-S20. CrossRef
- Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147–1171. CrossRef
- Bell BP, Kruszon-Moran D, Shapiro CN, et al.: Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine 2005, 23:5798–5806. CrossRef
- Saab S, Lee C, Shpaner A, Ibrahim AB: Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 2005, 12:101–105. This study evaluated the prevalence of HAV seropositivity among 473 patients with various causes of chronic liver disease. Overall, the seroprevalence of HAV was 55%; multivariable analysis identified older age, Hispanic or Asian race, and alcohol use as independent predictors of prior exposure to HAV. CrossRef
- Manfredi R, Calza L, Chiodo F: Changing epidemiology of hepatitis A in the Bologna metropolitan area, northern Italy: importance of counselling and prophylactic measures for the male homo/bisexual population. Clin Microbiol Infect 2005, 11:845–848. CrossRef
- Ochnio JJ, Patrick D, Ho M, et al.: Past infection with hepatitis A virus among Vancouver street youth, injection drug users and men who have sex with men: implications for vaccination programs. CMAJ 2001, 165:293–297.
- Villano SA, Nelson KE, Vlahov D, et al.: Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis 1997, 25:726–728.
- Siddiqui F, Mutchnick M, Kinzie J, et al.: Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001, 96:858–863. CrossRef
- Shim M, Khaykis I, Park J, Bini EJ: Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 2005, 42:688–695. This large retrospective cohort study highlights the need for public health programs to increase awareness of the importance of HAV vaccination in patients with chronic liver disease. CrossRef
- Kiefer LA, Honish A, Predy G, Talbot JA: The seroprevalence of hepatitis A and B in people testing positive for hepatitis C. CMAJ 2000, 162:207–208.
- Lugoboni F, Quaglio G, Pajusco B, et al.: Prevalence of hepatitis A among drug users in north-eastern Italy. Is vaccination necessary in low prevalence areas? Eur J Public Health 2005, 15:464–466. CrossRef
- Acharya SK, Batra Y, Bhatkal B, et al.: Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination. J Gastroenterol Hepatol 2003, 18:822–827. CrossRef
- Spada E, Genovese D, Tosti ME, et al.: An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users. J Hepatol 2005, 43:958–964. CrossRef
- Hadler SC: Global impact of hepatitis A infection: changing patterns. In Viral Hepatitis and Liver Disease. Edited by Hollinger FB, Lemon SM, Margolis H. Baltimore: Williams & Wilkins; 1991:14–20.
- Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290. This frequently cited prospective cohort study in Italy demonstrated that the case fatality rate was 35% in patients with chronic HCV infection who developed HAV superinfection. CrossRef
- Mele A, Tosti ME, Stroffolini T: Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:1771–1773. CrossRef
- Helbling B, Renner EL, Kammerlander R: Acute hepatitis A in patients with chronic hepatitis C [letter]. Ann Intern Med 1999, 131:314.
- Yao G: Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In Viral Hepatitis and Liver Disease. Edited by Hollinger FB, Lemon SM, Margolis H. Baltimore: Williams & Wilkins; 1991:76–78.
- Keeffe EB: Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995, 90:201–205.
- Keeffe EB, Iwarson S, McMahon BJ, et al.: Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998, 27:881–886. This multicenter study evaluated the efficacy and safety of HAV vaccination and found that the vaccine was well tolerated. Subjects with chronic HBV infection, chronic HCV infection, and chronic liver disease had seroconversion rates of 94% or greater after two doses of the HAV vaccine, but all of these subjects had lower geometric mean titers as compared with healthy controls. CrossRef
- Tsang SW, Sung JJ: Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment Pharmacol Ther 1999, 13:1445–1449. CrossRef
- Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB: Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001, 34:28–31. This important study highlights the need for early vaccination in patients with chronic liver disease. CrossRef
- Smallwood GA, Coloura CT, Martinez E, et al.: Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine? Transplant Proc 2002, 34:3289–3290. CrossRef
- Arslan M, Wiesner RH, Poterucha JJ, Zein NN: Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001, 72:272–276. CrossRef
- Syed NA, Hearing SD, Shaw IS, et al.: Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parenteral transmission. Eur J Gastroenterol Hepatol 2003, 15:901–906. CrossRef
- Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA: The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002, 97:721–728. CrossRef
- Myers RP, Gregor JC, Marotta PJ: The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 2000, 31:834–839. CrossRef
- Jacobs RJ, Meyerhoff AS, Saab S: Immunization needs of chronic liver disease patients seen in primary care versus specialist settings. Dig Dis Sci 2005, 50:1525–1531. CrossRef
- Chaudhari S, Tenner CT, Weinshel EH, Bini EJ: National survey of physician knowledge and attitudes regarding vaccination against hepatitis A and B in patients with chronic liver disease due to hepatitis C virus infection [abstract]. Gastroenterology 2005, 128:A555-A556.
- Chaudhari S, Tenner CT, Weinshel EH, Bini EJ: Barriers to vaccination against hepatitis A and hepatitis B in patients with chronic hepatitis C virus infection: a national survey of U.S. physicians [abstract]. Gastroenterology 2005, 127:A771.
- Vaccination against hepatitis a in patients with chronic liver disease
Current Hepatitis Reports
Volume 5, Issue 2 , pp 49-53
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links